$安帝君斯(AGEN)$ Agenus announced the dosing of the first COVID-19 patient with agenT-797, an allogeneic cell therapy, through its subsidiary, AgenTus Therapeutics. The trial is being led by Dr. Koen van Besien at Weill Cornell Medical College/New York Presbyterian Hospital. Separately, the FDA has also cleared agenT-797 to treat patients with cancer. Cancer trials are expected to commence shortly. As a subsidiary of Agenus, AgenTus currently has unique access to Agenus's portfolio of checkpoint antibodies and cancer vaccines which allows for optimal combinations with its cell therapies. This gives the company enormous flexibility to develop effective combinations with curative potential f or patients with cancer and infectious disease at a significant cost advantage.